Absci Corp

ABSI

Company Profile

  • Business description

    Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.

  • Contact

    18105 SE Mill Plain Boulevard
    VancouverWA98683
    USA

    T: +1 360 949-1041

    https://www.absci.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    140

Stocks News & Analysis

stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.
stocks

Investor Playbook: Can your portfolio handle what’s next?

Testing portfolio resilience in an uncertain market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.4039.10-0.42%
CAC 408,368.917.550.09%
DAX 4026,749.9521.93-0.08%
Dow JONES (US)52,347.5550.460.10%
FTSE 10010,902.5639.470.36%
HKSE23,767.28129.680.55%
NASDAQ25,136.27229.82-0.91%
Nikkei 22559,676.001,466.35-2.40%
NZX 50 Index14,303.77130.090.92%
S&P 5007,561.6730.73-0.40%
S&P/ASX 2009,044.7037.50-0.41%
SSE Composite Index3,595.2539.10-1.08%

Market Movers